Spiderwort

Spiderwort Biotechnologies Inc. is a biotechnology company working on plant-derived, cellulose-based biomaterials that are engineered into scaffolds for regenerative medicine and tissue engineering applications. The company positions its proprietary biomaterial platform as a framework applicable across regenerative medicine, tissue engineering and medical aesthetics.

Two products are described as under development. CelluBridge is a cellulose-based scaffold intended to support repair and regeneration of the spinal cord, pursued as a medical device program. CelluJuve is a cellulose-based dermal filler intended to support facial tissue augmentation and rejuvenation. Both programs remain pre-commercial according to the company's own descriptions.

The company's Chief Science Officer has presented the underlying approach publicly, including a TED talk on using plant-derived cellulose (for example from asparagus) as a scaffold material in the context of spinal cord injury.

Traction

As of December 2025, the company reported a peer-reviewed publication in Scientific Reports presenting findings on neural repair and motor recovery relating to its cellulose-based platform. In August 2025 it marked ten years since founding. Both named products, CelluBridge and CelluJuve, are described as under development rather than commercially available.

Latest developments

In December 2025 the company announced a publication in Nature's Scientific Reports reporting new findings on neural repair and motor recovery that it says reinforce its cellulose-based scaffold platform. In August 2025 it published a release marking its 10-year milestone.